A new publication involving goserelin appeared on August 3, 2026. The paper, titled "Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial," was published in the Journal of Clinical Oncology, the official journal of the American Society of Clinical Oncology.
The publication reports on the Phase II DISCOVARY trial, which evaluated darolutamide used alone and in combination with goserelin in patients with androgen receptor-positive salivary gland carcinoma. This is a peer-reviewed report of the trial as indexed under PubMed ID 42546251.
No specific findings, efficacy outcomes, or safety data from this publication are detailed here. Readers interested in the full results of the DISCOVARY trial, including any reported outcomes, should consult the original publication directly through the provided source link.
This brief reports only that the publication has been released, its title, its journal, and its date of appearance. It does not characterize or summarize any conclusions, benefits, or risks associated with the darolutamide and goserelin combination described in the trial. For general context on goserelin, see the compound overview.